MedPath

Special Drug Use-Results Survey of Gonalef (Subcutaneous injection 75/150, Subcutaneous injection pen 300/450/900) for Induction of Spermatogenesis in Male Hypogonadotropic Hypogonadism Patients

Phase 4
Conditions
Male Hypogonadotropic Hypogonadism
Registration Number
JPRN-UMIN000033659
Lead Sponsor
Merck Serono Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who do not give a full consent to this survey.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath